GlassScriptPhysician profile
Saad S Ahmad
NPI 1750562153
$2,154.60
in general payments reported to CMS, 2019-2025
28 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $181 · 2021: $324 · 2022: $302 · 2023: $279 · 2024: $128 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $552.15 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Astrazeneca Pharmaceuticals LP | $344.96 | 2019-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.32 | 2019-2023 | Ofev, Stiolto Respimat |
| Mylan Specialty L.P. | $118.99 | 2020-2024 | Yupelri |
| Grifols USA, LLC | $104.73 | 2019-2023 | Prolastin-C Liquid |
| Pfizer INC. | $100.00 | 2019 | |
| Pulmonx Corporation | $72.20 | 2020-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Insmed, INC. | $59.35 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $58.86 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.55 | 2020-2025 | Glassia |
| Viatris Specialty LLC | $42.43 | 2025 | Yupelri |
| Verona Pharma, INC. | $42.33 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $41.53 | 2019-2023 | Xywav |
| Shockwave Medical, INC | $39.55 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Regeneron Healthcare Solutions, INC. | $39.36 | 2023-2024 | Dupixent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $34.45 | 2019-2021 | |
| Neurotech Pharmaceuticals, INC. | $29.93 | 2025 | |
| Sunovion Pharmaceuticals INC. | $24.01 | 2020 | |
| Avanir Pharmaceuticals, INC. | $23.68 | 2022 | |
| Electromed, INC. | $20.01 | 2022 | |
| Axsome Therapeutics, INC. | $19.43 | 2023 | Sunosi |
| Merck Sharp & Dohme LLC | $19.32 | 2024 | Keytruda |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.97 | 2024 | Caplyta |
| Philips North America LLC | $15.68 | 2019 | |
| Shire North American Group INC | $14.69 | 2019 | |
| Inogen, INC. | $14.10 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.09 | 2021 | |
| Allergan, INC. | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.